Purchase this article with an account.
Marco H. Ji, Darius M. Moshfeghi, Laura Periman, David Kading, Cynthia Matossian, Gerald Walman, Scott Markham, Andy Mu, Ann Jayaram, Michael Gertner, Paul Karpecki, Neil J. Friedman; Novel Extranasal Tear Stimulation: Pivotal Study Results. Trans. Vis. Sci. Tech. 2020;9(12):23. https://doi.org/10.1167/tvst.9.12.23.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of iTEAR, a novel, portable, sonic external neuromodulation device, for the treatment of dry eye disease (DED).
This was a multicenter, open-label, single-arm clinical trial that included adult patients with DED with a Schirmer score of ≤10 mm in at least one eye. Enrolled subjects were instructed to apply the study device at least twice per day for 30 seconds bilaterally to the external nasal nerve. After the initial baseline visit, patients were followed up at days 3, 14, 30, 90, and 180. The primary efficacy endpoint was the Schirmer index (change from unstimulated to stimulated tear production as measured by the Schirmer test) at day 30. The major secondary endpoint was the change in symptoms of DED at day 30 evaluated using the Ocular Surface Disease Index (OSDI).
A total of 101 subjects evaluated at day 30 had a mean Schirmer index of 9.4 mm (95% confidence interval [CI], 7.4–11.3), and the baseline OSDI improved by an average of 14.4 (95% CI, 11.1–17.7). Both endpoints were highly statistically and clinically significant at all time points. There were two mild unanticipated adverse events definitely related to the device.
The safety and efficacy of the iTEAR device observed in this study support its indication for treating DED.
Neurostimulation has the potential to improve signs and symptoms of DED.
This PDF is available to Subscribers Only